UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 123

Sortiert nach

The screening and characterization of aptamer against gefitinib-resistant cells

Annals of oncology, 2017-04, Vol.28, p.ii10

2017

Link zum Volltext

Verfügbarkeit prüfen

Effects of BTK inhibitor on gefitinib-resistance non-small cell lung cancer

Annals of oncology, 2017-04, Vol.28, p.ii9

2017

Link zum Volltext

Verfügbarkeit prüfen

LBA52 Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase III ORIENT-15 study

Annals of oncology, 2021-09, Vol.32, p.S1330-S1330

2021

Link zum Volltext

Verfügbarkeit prüfen

Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial

Annals of oncology, 2014-12, Vol.25 (12), p.2385-2391

2014

Link zum Volltext

Verfügbarkeit prüfen

Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG–0803)

Annals of oncology, 2013-04, Vol.24 (4), p.993-999

2013

Link zum Volltext

Verfügbarkeit prüfen

Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial

Annals of oncology, 2021-04, Vol.32 (4), p.512-521

2021

Link zum Volltext

Verfügbarkeit prüfen

Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)

Annals of oncology, 2015-09, Vol.26 (9), p.1877-1883

2015

Link zum Volltext

Verfügbarkeit prüfen

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

Annals of oncology, 2015-09, Vol.26 (9), p.1883-1889

2015

Link zum Volltext

Verfügbarkeit prüfen

CTONG 1103: Erlotinib versus gemcitabine plus cisplatin as neo-adjuvant treatment for stage IIIA-N2 EGFR-mutation non-small cell lung cancer (EMERGING): A randomised study

Annals of oncology, 2018-10, Vol.29, p.viii738-viii738

2018

Link zum Volltext

Verfügbarkeit prüfen

Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy

Annals of oncology, 2018-04, Vol.29 (4), p.945-952

2018

Link zum Volltext

Verfügbarkeit prüfen

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)

Annals of oncology, 2013-06, Vol.24 (6), p.1615-1622

2013

Link zum Volltext

Verfügbarkeit prüfen

TP53 GOF mutations predict good response and prolonged survival to bevacizumab treatment in metastatic colorectal cancer

Annals of oncology, 2018-11, Vol.29, p.ix118-ix118

2018

Link zum Volltext

Verfügbarkeit prüfen

Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern China

Annals of oncology, 2019-10, Vol.30 (10), p.1630-1637

2019

Link zum Volltext

Verfügbarkeit prüfen

Attributable causes of cancer in China

Annals of oncology, 2012-11, Vol.23 (11), p.2983-2989

2012

Link zum Volltext

Verfügbarkeit prüfen

Biomarker-integrated study of single agent targeting molecular alterations of PI3KCA, MET, ALK, ROS1, KRAS, NRAS or BRAF in advanced NSCLC: Phase 2 umbrella trial in China (CTONG1505)

Annals of oncology, 2018-11, Vol.29, p.ix113-ix113

2018

Link zum Volltext

Verfügbarkeit prüfen

Lenvatinib acts as the salvage therapy for advanced hepatocellular carcinoma

Annals of oncology, 2018-11, Vol.29, p.ix57-ix57

2018

Link zum Volltext

Verfügbarkeit prüfen

Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial

Annals of oncology, 2021-01, Vol.32 (1), p.85-96

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of tepotinib + gefitinib (TEP+GEF) in MET-positive (MET+)/epidermal growth factor receptor (EGFR)-mutant (MT) non-small cell lung cancer (NSCLC)

Annals of oncology, 2018-10, Vol.29, p.viii493-viii493

2018

Link zum Volltext

Verfügbarkeit prüfen

Randomized, phase III trial comparing adjuvant gemcitabine (Gem) versus Gem plus chemoradiation (CCRT) in curatively resected pancreatic ductal adenocarcinoma (PDAC): A Taiwan cooperative oncology group study

Annals of oncology, 2018-10, Vol.29, p.viii210-viii210

2018

Link zum Volltext

Verfügbarkeit prüfen

Tepotinib + gefitinib (TEP+GEF) in MET+/epidermal growth factor receptor (EGFR)-mutant non-small lung cancer (NSCLC): Phase II data

Annals of oncology, 2018-11, Vol.29, p.ix159-ix159

2018

Link zum Volltext

Verfügbarkeit prüfen

AURA17 study of osimertinib in Asia-Pacific patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC): Updated phase II results including overall survival (OS)

Annals of oncology, 2018-11, Vol.29, p.ix157-ix157

2018

Link zum Volltext

Verfügbarkeit prüfen

Co-occurring alterations in driver genes impact on EGFR-targeted therapy among patients with EGFR-mutant advanced non–small cell lung cancer

Annals of oncology, 2018-11, Vol.29, p.ix158-ix159

2018

Link zum Volltext

Verfügbarkeit prüfen

Comparison of tissue-based and liquid biopsy genomic tests to guide lung cancer therapy: Asian experience

Annals of oncology, 2018-10, Vol.29, p.viii480-viii481

2018

Link zum Volltext

Verfügbarkeit prüfen

Osimertinib in advanced or metastatic non-small cell lung cancer patients with EGFR T790M mutation after treatment with EGFR-TKI: Interim analysis of China cohort from the single-arm, open-label, international, multi-center real-world ASTRIS study

Annals of oncology, 2018-11, Vol.29, p.ix158-ix158

2018

Link zum Volltext

Verfügbarkeit prüfen

1266P Genetic profiling of cell-free DNA from pleural effusion in advanced lung cancer as a surrogate for tumor tissue and revealed additional clinical actionable targets

Annals of oncology, 2021-09, Vol.32, p.S990-S990

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 123

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieThin Solid Films

Zeitschrift / SerieAnnals Of Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(123)
Mit Volltextzugriff
(123)

Publikationsform

Artikel
(123)

Sprache

Englisch
(123)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Humans
(15)
Life Sciences & Biomedicine
(14)
Oncology
(14)
Science & Technology
(14)
Female
(13)
Male
(13)
Adult
(10)
Middle Aged
(9)
Aged
(8)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(8)
Erbb Receptors - Genetics
(7)
Antineoplastic Agents
(6)
Biological And Medical Sciences
(6)
Carcinoma, Non-Small-Cell Lung - Genetics
(6)
Chemotherapy
(6)
Medical Sciences
(6)
Pharmacology. Drug Treatments
(6)
Disease-Free Survival
(5)
Erlotinib
(5)
Non-Small-Cell Lung Cancer
(5)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Menü

Weitere Dienste

Einstellungen

The screening and characterization of aptamer against gefitinib-resistant cells

Effects of BTK inhibitor on gefitinib-resistance non-small cell lung cancer

LBA52 Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase III ORIENT-15 study

Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial

Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG–0803)

Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial

Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

CTONG 1103: Erlotinib versus gemcitabine plus cisplatin as neo-adjuvant treatment for stage IIIA-N2 EGFR-mutation non-small cell lung cancer (EMERGING): A randomised study

Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)

TP53 GOF mutations predict good response and prolonged survival to bevacizumab treatment in metastatic colorectal cancer

Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern China

Attributable causes of cancer in China

Biomarker-integrated study of single agent targeting molecular alterations of PI3KCA, MET, ALK, ROS1, KRAS, NRAS or BRAF in advanced NSCLC: Phase 2 umbrella trial in China (CTONG1505)

Lenvatinib acts as the salvage therapy for advanced hepatocellular carcinoma

Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial

Phase II study of tepotinib + gefitinib (TEP+GEF) in MET-positive (MET+)/epidermal growth factor receptor (EGFR)-mutant (MT) non-small cell lung cancer (NSCLC)

Randomized, phase III trial comparing adjuvant gemcitabine (Gem) versus Gem plus chemoradiation (CCRT) in curatively resected pancreatic ductal adenocarcinoma (PDAC): A Taiwan cooperative oncology group study

Tepotinib + gefitinib (TEP+GEF) in MET+/epidermal growth factor receptor (EGFR)-mutant non-small lung cancer (NSCLC): Phase II data

AURA17 study of osimertinib in Asia-Pacific patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC): Updated phase II results including overall survival (OS)

Co-occurring alterations in driver genes impact on EGFR-targeted therapy among patients with EGFR-mutant advanced non–small cell lung cancer

Comparison of tissue-based and liquid biopsy genomic tests to guide lung cancer therapy: Asian experience

Osimertinib in advanced or metastatic non-small cell lung cancer patients with EGFR T790M mutation after treatment with EGFR-TKI: Interim analysis of China cohort from the single-arm, open-label, international, multi-center real-world ASTRIS study

1266P Genetic profiling of cell-free DNA from pleural effusion in advanced lung cancer as a surrogate for tumor tissue and revealed additional clinical actionable targets

Aktive Filter

Suchergebnisse filtern